In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $78.12 down -2.78% from its previous closing price of $80.35. In other words, the price has decreased by -$2.78 from its previous closing price. On the day, 0.54 million shares were traded. KYMR stock price reached its highest trading level at $80.53 during the session, while it also had its lowest trading level at $77.28.
Ratios:
For a deeper understanding of Kymera Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.38 and its Current Ratio is at 7.38. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 24, 2025, B. Riley Securities reiterated its Buy rating and also lowered its target price recommendation from $60 to $80.
On October 21, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $81.Mizuho initiated its Outperform rating on October 21, 2025, with a $81 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 17 ’25 when Esposito Pamela sold 27,563 shares for $82.16 per share. The transaction valued at 2,264,480 led to the insider holds 0 shares of the business.
PAMELA ESPOSITO bought 27,563 shares of KYMR for $2,320,529 on Dec 17 ’25. On Dec 10 ’25, another insider, Booth Bruce, who serves as the Director of the company, sold 229,809 shares for $91.73 each. As a result, the insider received 21,080,724 and left with 686,477 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 6249524224 and an Enterprise Value of 5198972928. For the stock, the TTM Price-to-Sale (P/S) ratio is 141.04 while its Price-to-Book (P/B) ratio in mrq is 5.92. Its current Enterprise Value per Revenue stands at 118.874 whereas that against EBITDA is -16.169.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.23, which has changed by 0.96502817 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $103.00, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 11.95%, while the 200-Day Moving Average is calculated to be 62.47%.
Shares Statistics:
For the past three months, KYMR has traded an average of 936.81K shares per day and 846560 over the past ten days. A total of 71.74M shares are outstanding, with a floating share count of 65.71M. Insiders hold about 16.77% of the company’s shares, while institutions hold 91.62% stake in the company. Shares short for KYMR as of 1765756800 were 7894340 with a Short Ratio of 8.43, compared to 1763078400 on 8581283. Therefore, it implies a Short% of Shares Outstanding of 7894340 and a Short% of Float of 11.88.
Earnings Estimates
The firm’s stock currently is rated by 20.0 analysts. The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.76 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$2.77 and -$3.86 for the fiscal current year, implying an average EPS of -$3.46. EPS for the following year is -$3.71, with 21.0 analysts recommending between -$2.99 and -$6.01.
Revenue Estimates
A total of 21 analysts believe the company’s revenue will be $14.63M this quarter.It ranges from a high estimate of $52.24M to a low estimate of $3M. As of. The current estimate, Kymera Therapeutics Inc’s year-ago sales were $7.39MFor the next quarter, 21 analysts are estimating revenue of $10.62M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $5M.
A total of 22 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $105M, while the lowest revenue estimate was $39.1M, resulting in an average revenue estimate of $53.36M. In the same quarter a year ago, actual revenue was $47.07MBased on 22 analysts’ estimates, the company’s revenue will be $47.38M in the next fiscal year. The high estimate is $100M and the low estimate is $10M.
